

Morgan Lewis



BLOCKBUSTER BIOLOGICS REVIEW Quarterly Update – July 2019

Christopher J. Betti, Ph.D. Robin M. Silva Jennifer M. Dienes

© 2019 Morgan, Lewis & Bockius LLP



Welcome to our ongoing updates relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. We hope you find this 2Q 2019 update informative. As always, please feel free to reach out to us with any questions.

Chris, Robin, and Jennifer

Table of Contents

1. Quarterly Post-Grant Update	2
A Inter Partes Reviews (IPRs)	5
i. Developments	6
ii. IPRs by Reference Product	8
iii. IPR Timeline	9
iv. Types of Claims Being Challenged	10
v. IPR Scorecard – Institution	11
vi. IPR Scorecard – Final Written Decisions (FWDs)	13
vii. IPR Appeals	15
B Post-Grant Reviews (PGRs)	22

Table of Contents (cont.)

2.	US Biosimilar-Related Patent Litigations	23							
	i. Developments	24							
	ii. Scorecard	31							
3	B Legislative Updates								
4	Biosimilar Approvals and Launches								
5	Contacts	52							
6	Appendix – IPR Detailed Analysis	55							

INTER PARTES REVIEWS (IPRS)

> Quick statistics:


- The current institution rate for IPR challenges to patents that claim biologics is 45% (excludes IPRs that have settled or otherwise been terminated)
- > Of those IPRs instituted and that have gone to final written decision (FWD), 47% have resulted in the challenged claims being held unpatentable, with 22% having mixed results

IPRs: Developments (cont.)


> NEULASTA IPR Update:

- On May 20, 2019, the PTAB denied Apotex's request for rehearing in its IPR petition (IPR 2016-01542) challenging a protein refolding process patent owned by Amgen, US Patent No. 8,952,138
 - > However, the Board sua sponte modified its FWD to find claim 18 unpatentable as obvious
- > On June 8, 2019, Fresenius Kabi filed an IPR petition (IPR 2019-01183) challenging another purification process patent owned by Amgen, US Patent No. 9,643,997

IPRs by Reference Product




IPR Timeline



Morgan Lewis

(September–October)

Types of Claims Being Challenged



IPR Scorecard – Institution

Product (# IPRs)	Challenger	Pend. Inst.	Pet. Not Inst.	Sett. Term.	Inst.*
	Amgen	0	2	-	-
Humira (22)	BI	0	-	-	2
nullia (22)	Coherus	0	5	2	3
	Sandoz	0	6	2	-
	BI	0	1	2	-
Rituxan (27)	Celltrion	0	6	2	3
	Pfizer	0	5	3	3
	Sandoz	0	2	-	-
	Phigenix	0	1	-	1
	Mylan	0	-	2	-
	Hospira	0	1	-	5
Herceptin (36)	Celltrion	0	-	1	6
	Pfizer	0	5	2	4
	Samsung	0	1	-	5
	BI	0	-	2	-
Tysabri (3)	Swiss Pharma	0	3	-	-

Institution rate = 35/78 = 45%

Morgan Lewis

* IPRs instituted but later settled or otherwise terminated are not included

IPR Scorecard – Institution (cont.)

Product (# IPRs)	Challenger	Pend. Inst.	Pet. Not Inst.	Sett. Term.	Inst.*
Avastin (2)	Hospira	0	1	-	1
Orencia (1)	Momenta	0	-	-	1
	Apotex	0	-	-	1
Neulasta (4)	Fresenius Kabi	1	-	-	-
	Kashiv Biosciences	2	-	-	-
Enbrel (3)	Kyle Bass	0	1	-	-
	Coherus	0	2	-	-
Epogen (1)	Hospira	0	-	1	-
Keytruda (4) Merck		0 0		4	-
TOTALS		3	42	23	35

Institution rate = 35/78 = 45%

* IPRs instituted but later settled or otherwise terminated are not included

IPR Scorecard – Final Written Decisions (FWDs)

Product (# IPRs)	Challenger	Inst.*	FWD (invalid)	FWD (upheld)	Mixed
	Amgen	-	-	-	-
Humira (22)	BI	2	2	-	-
nuillia (22)	Coherus	3	3	-	-
	Sandoz	-	-	-	-
	BI	-	-	-	-
Rituxan (27)	Celltrion	3	1	1	-
	Pfizer	3	1	1	-
	Sandoz	-	-	-	-
	Phigenix	1	-	1	-
	Mylan	-	-	-	-
	Hospira	5	3	2	-
Herceptin (36)	Celltrion	6	2	2	2
	Pfizer	4	1	-	2
	Samsung	5	1	2	2
	BI	-	-	-	-

Invalidation rate = 15/32 = 47%, w/ mixed results 22% * IPRs instituted but later settled or otherwise terminated are not included

IPR Scorecard – FWDs (cont.)

Product (# IPRs)	Challenger	Inst.*	FWD (invalid)	FWD (upheld)	Mixed
Tysabri (3)	Swiss Pharma	-	-	-	-
Avastin (2)	Hospira	1	1	-	-
Orencia (1)	Orencia (1) Momenta		-	1	-
Neulasta (4)	Apotex	1	-	-	1
Enbrel (3)	Kyle Bass	-	-	-	-
	Coherus	-	-	-	-
Epogen (1)	Hospira	-	-	-	-
Keytruda (4)	Merck	_	-	_	-
TOTALS		35	15	10	7

Invalidation rate = 15/32 = 47%, w/ mixed results 22% * IPRs instituted but later settled or otherwise terminated are not included

Blockbuster Biologics: IPR Appeals (Humira)

Patent Owner	Challenger	Patent No.	Biologic	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
AbbVie	Coherus	8,889,135	Humira	2016-00172 (2017-2304)	Claims Invalid	All of these appeals have been consolidated
AbbVie	Boehringer Ingelheim	8,889,135	Humira	2016-00408 (2017-2362)	Claims Invalid	 AbbVie challenged the constitutionality of the application of the America
AbbVie	Boehringer Ingelheim	8,889,135	Humira	2016-00409 (2017-2363)	Claims Invalid	Invents Act (AIA) in these cases
AbbVie	Coherus	9,017,680	Humira	2016-00188 (2017-2305)	Claims Invalid	 US Attorney General has intervened Coherus withdrew as party
AbbVie	Coherus	9,017,987	Humira	2016-00189 (2017-2306)	Claims Invalid	due to settlement • PTO intervened

Blockbuster Biologics: IPR Appeals (Rituxan)

Patent Owner	Challenger	Patent No.	Biologic	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Genentech	Celltrion	7,820,161	Rituxan	2016-1614 (2018-1885) 2017-01115 joined (2018-1924)	Claims Valid	 Appeal No. 2016-1614 voluntarily dismissed Appeal No. 2018-1885 dismissed with prejudice as part of Settlement and License Agreement Appeal No. 2018-1924 dismissed as part of litigation settlement (Case No. 18-574-RMB-KMW (D.N.J.))
Biogen	Pfizer	8,821,873	Rituxan	2017-01168 (2019-1364)	Claims Invalid	 Biogen challenging constitutionality of IPRs Pfizer not participating in appeal PTO intervened in appeal Parties voluntarily dismissed appeal Issues fully briefed; oral argument being scheduled

Blockbuster Biologics: IPR Appeals (Herceptin)

Patent Owner	Challenger	Patent No.	Biologic	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Genentech	Hospira	7,807,799	Herceptin	2016-01837 (2018-1933)	Claims Invalid	 Includes constitutional challenge regarding retroactive application of IPR to pre-AIA patent PTO intervened Issues have been briefed Oral argument scheduled for August 05, 2019
Genentech	Hospira	7,846,441	Herceptin	2017-00731 (2019-1263)	Claims Invalid	 Hospira withdrew as party due to settlement PTO intervened Opening brief filed
Genentech	Celltrion	7,846,441	Herceptin	2017-01121 (2019-1267)	Claims Invalid	PTO intervenedOpening brief filed
Genentech	Hospira	6,627,196	Herceptin	2017-00804/ No. 2017-01958 joined (2019- 1173)	Claims Valid	 Lead case – consolidated with 2019-1174 Appeal voluntarily dismissed

Blockbuster Biologics: IPR Appeals (Herceptin) (cont.)

Patent Owner	Challenger	Patent No.	Biologic	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Genentech	Hospira	7,371,379	Herceptin	2017-00805/ No. 2017-01959 joined (2019- 1174)	Claims Valid	Consolidated with 2019-1173Appeal voluntarily dismissed
Genentech	Celltrion	6,627,196	Herceptin	2017-01139 (2019-1258)	Claims Valid	Consolidated with 2019-1259Parties dismissed appeal
Genentech	Celltrion	7,371,379	Herceptin	2017-01140 (2019-1259)	Claims Valid	Consolidated with 2019-1258Parties dismissed appeal
Genentech	Hospira	7,892,549	Herceptin	2017-00737/ No. 2017-01960 joined (2019- 1265)	Claims Invalid	 Hospira withdrew as party due to settlement Samsung Bioepsis withdrew as party Opening brief filed
Genentech	Celltrion	7,892,549	Herceptin	2017-01122 (2019-1270)	Claims Invalid	PTO allowed to interveneOpening brief filed

Blockbuster Biologics: IPR Appeals (Neulasta)

Patent Owner	Challenger	Patent No.	Biologic	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Amgen	Apotex	8,952,138	Neulasta	2016-01542 (2019-2171)	Claims Invalid	Amgen filed Notice of Appeal

Blockbuster Biologics: IPR Appeals (Avastin)

Patent Owner	Challenger	Patent No.	Biologic	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Genentech	Hospira	7,622,115	Avastin	2016-01771 (2018-1959)	Claims Invalid	 Includes constitutional challenge regarding retroactive application of IPR to pre-AIA patent United States intervened Oral argument held July 11, 2019

Blockbuster Biologics: IPR Appeals (Orencia)

Patent Owner	Challenger	Patent No.	Biologic	IPR No. (Appeal No.)	Decision Appealed	Status of Appeal
Bristol-Myers Squibb	Momenta	8,476,239	Orencia	2015-01537 (2017-1694)	Claims Valid	 Federal Circuit dismissed appeal for lack of standing/jurisdiction and for mootness

Post-Grant Reviews (PGRs)

 Only one PGR has been filed to date in connection with a blockbuster biologic (US 9,856,287)

Product (# IPRs)	Challenger	Pend. Inst.	Pet. Not Inst.	Sett. Term.	Inst.
Neupogen (1)	Adello/Apotex	-	-	-	1

US BIOSIMILAR-RELATED PATENT LITIGATIONS

US Biosimilar Litigations: Developments

> HUMIRA Litigation:

- > Boehringer Ingelheim and AbbVie entered into a settlement agreement granting Boehringer Ingelheim a license to AbbVie's intellectual property to commercialize its Humira biosimilar
 - > Under the agreement, Boehringer Ingelheim's Cyltezo adalimumab biosimilar will not enter the US market until July 1, 2023
 - > The settlement resolves all Humira-related patent litigation between the parties in the US

US Biosimilar Litigations: Developments (cont.)

> Summary of Humira Biosimilar Settlements

Party	US Market Entry	EP Market Entry
Amgen	January 31, 2023	October 16, 2018
Biogen and Samsung Bioepis	June 30, 2023	October 16, 2018
Mylan	July 31, 2023	
Sandoz	September 30, 2023	October 16, 2018
Fresenius Kabi	September 30, 2023	Upon approval
Momenta	November 20, 2023	
Pfizer	November 20, 2023	
Coherus	December 15, 2023	
Boehringer Ingelheim	July 1, 2023	

> NEUPOGEN Litigation:

- In Amgen v. Coherus, No. 18-1993, on July 29, 2019 the Federal Circuit affirmed the District Court's dismissal of Amgen's complaint for failure to state a claim because prosecution history estoppel bars Amgen from succeeding on its infringement claim under the doctrine of equivalents
 - The USPTO granted the asserted patent only after Amgen argued that its invention required the use of a particular pair of salts. The Federal Circuit held that Amgen cannot now claim rights to additional salt pairs, such as those used by Coherus.

> NEULASTA Litigation:

- > In *Amgen v. Sandoz*, No. 18-1551, on May 8, 2019 the Federal Circuit affirmed the District Court's grant of summary judgment of non-infringement in favor of Sandoz
 - > On June 7, 2019, Amgen filed a petition for rehearing en banc challenging the panel's reasoning that the doctrine of equivalents was inapplicable
- > Amgen filed a BPCIA complaint against Tanvex BioPharma USA, Inc., No. 19-cv-1374-AJB-MSB, in the Southern District of California alleging infringement of US Patent No. 9,856,287 directed to methods of refolding proteins

> HERCEPTIN Litigation:

- > On June 28, 2019 Samsung Bioepis and Genentech settled their patent disputes regarding Samsung Bioepis's Herceptin biosimilar, Ontruzant (trastuzumab-dttb)
 - > The parties voluntarily dismissed the pending appeal before the Federal Circuit, Nos. 2019-1173 and 2019-1174
 - > They stipulated to the dismissal of *Genentech v. Samsung Bioepis*, No. 18-1363
 - Samsung Bioepsis also withdrew from the consolidated appeal, Genentech v. Iancu, No. 2019-1265

US Biosimilar Litigations: Developments (cont.)

> HERCEPTIN Litigation:

- > On July 10, 2019, Genentech filed motions for a Temporary Restraining Order and Preliminary Injunction against Amgen in *Genentech v. Amgen*, No. 18-924-CFC (D. Del.)
 - > On July 22, 2019, the District Court denied those motions
 - > Genentech failed to establish irreparable harm due, in part, to undue delay in seeking a preliminary injunction
 - > FDA approved Kanjinti on June 13, 2019, but Genentech did not file its motion until 14 months after receiving the Notice of Commercial Marketing, three months after receiving a fairly specific launch date, and almost one month after FDA approval
 - > Damages for sales in the next four months should be quantifiable in view of the existing licenses to Mylan, Celltrion, and Pfizer

US Biosimilar Litigations: Developments (cont.)

> Products in patent litigation that we are monitoring include:

- > Humira > Enbrel
- > Rituxan

> Epogen

> Avastin

- > Herceptin
- > Neupogen
- > Remicade

- > Neulasta
- > These litigations are summarized on the following slides

Blockbuster Biologics: US Litigation Scorecard – Humira

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	AbbVie v. Amgen	No. 16-666-MSG (D. Del.)	10	M, F, U, C	 Settled – US launch of Amjevita expected January 31, 2023
	AbbVie v. Boehringer Ingelheim	No. 17-1065-SLR (D. Del.)	8	M, F, U, C	 Parties stipulated to dismissal
Humira (4)	AbbVie v. Sandoz	No. 18-12668 (D.N.J.)	2	U, F	 Settled – US launch of Hyrimoz expected September 20, 2023
	Coherus v. Amgen	No. 19-00139 (D. Del.)	3	С	Scheduling Order entered

Blockbuster Biologics: US Litigation Scorecard – Rituxan

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Genentech v. Sandoz	No. 17-13507-RMB-KMW (D.N.J.)	24	M, U, C	 Stipulated dismissal without prejudice Sandoz decided not to pursue its FDA submission for its biosimilar
Rituxan (4)	Celltrion v. Genentech	No. 18-276-JSW (N.D. Cal.) No. 18-2161 (Fed. Cir.) (consolidated with No. 18-2160)	37	M, U	 Genentech's Motion to Dismiss granted Final judgment appealed to Federal Circuit Appeal voluntarily dismissed
	Genentech v. Celltrion	No. 18-574-RMB-KMW (D.N.J.)	40	M, U, C	Settled
	Genentech v. Celltrion	(consolidated with No. 18-574-RMB-KMW)	18 (Claims mirror those of No. 18-574 – filed to ensure compliance with BPCIA)	M, U, C	• Settled

Blockbuster Biologics: US Litigation Scorecard – Herceptin

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Celltrion v. Genentech	No. 18-274-JSW (N.D. Cal.) No. 18-2160 (Fed. Cir.)	38	M, U, C	 Genentech's Motion to Dismiss granted Final Judgment appealed to Federal Circuit Appeal voluntarily dismissed
Herceptin (6)	Genentech v. Celltrion	No. 18-095-CFC (D. Del.)	40	M, U, C	 All of the Delaware cases are before Judge Connolly and being coordinated <i>Markman</i> hearing April 2019 Trial set for December 2019 Lead case Settled
	Genentech v. Pfizer	No. 17-1672-CFC (D. Del.)	40	M, U, C	• Settled

Blockbuster Biologics: US Litigation Scorecard – Herceptin (cont.)

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Genentech v. Amgen	No. 18-924-CFC (D. Del.)	37	M, U, C	 Early discovery Claims regarding expired patents and Amgen's defense of unclean hands/inequitable conduct voluntarily dismissed Court denied Genentech's Motion for a TRO and lifted the standstill order given July 10, 2019
Herceptin (6)	Genentech v. Celltrion	No. 18-1025-CFC (D. Del.)	40	M, U, C	Settled
	Genentech v. Samsung Bioepis	No. 18-01363-CFC (D. Del.)	21	M, U, C	Dismissed due to settlement

Blockbuster Biologics: US Litigation Scorecard – Neupogen

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neupogen (6)	Amgen v. Sandoz	No. 14-04741-RS (N.D. Cal.) No. 15-1499 (Fed. Cir.) Nos. 15-1039, 15-1195 (Supreme Court) No. 18-1551 (Fed. Cir.)	1	Μ	 Complaint alleged Sandoz violated the BPCIA by (1) failing to provide its aBLA and manufacturing information within 20 days of FDA acceptance and (2) providing notice of commercial marketing before FDA approval of its aBLA District Court ruled in favor of Sandoz; on appeal, Federal Circuit and Supreme Court did the same District Court subsequently granted Sandoz's Motion for Summary Judgment of Non- infringement; Affirmed on appeal Petition for rehearing en banc pending
	Amgen v. Apotex	No. 15-62081-JIC (S.D. Fla.)	2	M, C	 Consolidated with Amgen v. Apotex pegfilgrastim (Neulasta) litigation, No. 15- 61631, where District Court entered judgment of non-infringement for Sandoz Affirmed

Blockbuster Biologics: US Litigation Scorecard – Neupogen (cont.)

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Amgen v. Adello	No. 18-3347-JMV-SCM (D.N.J.)	17	М	 Amended Complaint filed, reducing number of patents to four and naming Amneal Pharmaceuticals as co-defendant Amneal moved to dismiss Amended Complaint for failure to state a daim and lack of subject matter jurisdiction Claim construction briefed Parties stipulated to dismissal of causes of action directed to US Patent No. 8,952,138
Neupogen (6)	Amgen v. Hospira	No. 18-1064 (D. Del.)	1	Μ	 Scheduling Order issued: Close of fact discovery is August 23, 2019 <i>Markman</i> hearing held May 15, 2019 Trial is set for June 15, 2020
	Sandoz v. Amgen	No. 19-00977 (N.D. Cal.)	1	М	 Sandoz voluntarily dismissed action without prejudice

Blockbuster Biologics: US Litigation Scorecard – Neupogen (cont.)

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neupogen (6)	Amgen v. Tanvex	No. 19-1374-AJB-MSB (S.D. Cal.)	1	М	Complaint filed

Blockbuster Biologics: US Litigation Scorecard – Neulasta

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neulasta (6)	Amgen v. Apotex	No. 15-61631-JIC (S.D. Fla.) No. 16-1308 (Fed. Cir.) No. 17-1010 (Fed. Cir.) No. 16-332 (Supreme Court)	2	M, F	 Amgen found not to infringe Supreme Court denied Apotex's Petition for Certiorari Federal Circuit affirmed district court ruling District Court: Granted Amgen's Motion for Summary Judgment re: invalidity defenses except non-enablement Awarded judgment of non-infringement for Apotex Dismissed Apotex's non-enablement defense without prejudice
	Amgen v. Sandoz	No. 16-1276-SRC-CLW (D.N.J.)	Litigation over whether Sandoz violated BPCIA	NA	 Dismissed after Sandoz restarted patent dance negotiations

Blockbuster Biologics: US Litigation Scorecard – Neulasta (cont.)

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Amgen v. Sandoz	No. 16-02581-RS (N.D. Cal.) No. 18-1552 (Fed. Cir.) consolidated with No. 18-1551	2	M, F	 On appeal, fully briefed, pending scheduling of oral argument Summary Judgment of Non-infringement granted for Sandoz Affirmed
Neulasta (6)	Amgen v. Coherus	No. 17-546-LPS (D. Del.) No. 18-1993 (Fed. Cir.)	1	М	 Court granted Coherus's Motion to Dismiss for Failure to State a Claim Judgment entered against Amgen and case was dismissed Affirmed

Blockbuster Biologics: US Litigation Scorecard – Neulasta (cont.)

Produ (# litigati		Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Neulasta	a (6)	Amgen v. Mylan	No. 17-1235-MRH (W.D. Pa.)	2	М	 Claim Construction Order issued Amgen ordered to file with infringement contentions a statement identifying facts relied on outside of Mylan's FDA filings Motion for Summary Judgment of Non- infringement of US Patent No. 9,643,997 filed – ruling deferred Abeyance in place pending further order to be issued around Aug. 14, 2019
		Amgen v. Apotex	No. 18-61828 (S.D. Fla.)	1	Μ	 District Court denied Apotex's motion to dismiss Amgen's complaint for failure to state a claim Joint Claim Construction Statement filed

Blockbuster Biologics: US Litigation Scorecard – Enbrel

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Enbrel (1)	Immunex v. Sandoz	No. 16-01118-CCC-JBC (D.N.J.)	5	C, F, U	 Before trial, Sandoz stipulated to infringement to certain asserted claims of two of the five patents-in-suit Bench trial held September 2018

Blockbuster Biologics: US Litigation Scorecard – Epogen

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Epogen (1)	Amgen v. Hospira	No. 15-839-RGA (D. Del.) No. 16-2179 (Fed. Cir.) (appeal was dismissed) No. 19-1067 and No. 19-1102 (Fed. Cir.)	2	С, М	 Jury found infringement and awarded \$70M in damages Final judgment entered with pre- and post-judgment interest Hospira appealed, arguing that all of its batches of product should be subject to the safe harbor provision about which the jury was given erroneous instructions Amgen responded that there was sufficient evidence supporting the jury's finding that only seven of the 21 drug batches qualified for safe harbor Oral argument being scheduled

Blockbuster Biologics: US Litigation Scorecard – Avastin

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
	Genentech v. Amgen	No. 17-165-GMS (D. Del.)	Litigation over violations of the BPCIA	NA	 Dismissed Complaint without prejudice
	Amgen v. Genentech	No. 17-7349-GW-AGR (C.D. Cal.)	27	M, C, F, U	 Genentech's Motion to Dismiss for Lack of Subject Matter Jurisdiction granted
Avastin (5)	Genentech v. Amgen	No. 17-1407-CFC (D. Del.)	24	M, C, F, U	 Early pleadings and discovery Consolidated with No. 17-1471 Lead case Post-<i>Markman</i> Claim Construction Brief filed Trial set for July 13, 2020 Mediation conference set for Aug. 23, 2019 Evidentiary hearing re: indefiniteness set for Oct. 7, 2019
	Genentech v. Amgen	No. 17-1471-CFC (D. Del.)	25	M, C, F, U	Consolidated with No. 17-1407
	Genentech v. Pfizer	. ,	22	M, C, F, U	Complaint filed April 5, 2019

Blockbuster Biologics: US Litigation Scorecard – Remicade

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Remicade (5)	Janssen v. Celltrion	No. 15-10698-MLW (D. Mass.) No. 17-1120 (Fed. Cir.)	2	C, U	 Partial Summary Judgment of Invalidity granted with respect to one patent ('471 patent) Federal Circuit dismissed appeal as moot upon affirming decision in appeal (No. 17-1257) from ex parte reexamination ruling by USPTO that same patent's claims are unpatentable for double patenting Dismissed without prejudice in favor of Case No. 17-11008
	Janssen v. Celltrion	No. 16-11117-MLW (D. Mass.)	1	M (cell culture media)	 Dismissed without prejudice in favor of Case No. 17-11008
	Janssen v. HyClone	No. 16-00071-BCW (D. Utah)	1	M (cell culture media)	• Stayed pending resolution of D. Mass. case

Blockbuster Biologics: US Litigation Scorecard – Remicade (cont.)

Product (# litigations)	Case Name	Case No. (Jurisdiction)	# of Asserted Patents	Types of Claims	Status
Remicade (5)	Janssen v. Celltrion	No. 17-11008 (D. Mass.) No. 18-2350 (Fed. Cir.) Lead appeal (No. 18-2321)	1	M (cell culture media)	 Judgment entered for defendants after court allowed Motion for Summary Judgment of Non-infringement based on ensnarement On appeal (both parties) Fully briefed
	Janssen v. Samsung Bioepis	No. 17-3524-MCA-SCM (D.N.J.)	3	Μ	Janssen voluntarily dismissed its patent infringement claimsSuit dismissed with prejudice

LEGISLATIVE UPDATES

> Proposed Legislation:

- > <u>Terminating the Extension of Rights Misappropriated (Term) Act of 2019</u>
 - > Bipartisan bill proposed on June 11, 2019 by Representatives Hakeem Jeffries and Doug Collins to address the rising cost of prescription drugs by limiting patent evergreening
 - > Currently, a generic drug manufacturer must prove why a new patent should not be granted to a brand if it intends to enter the market before patent expiration
 - The proposed legislation shifts the burden of proof to the brand, which is presumed to have disclaimed the term of each patent listed after the date on which the first patent expires, unless the later patents are shown to be patentably distinct

> Proposed Legislation:

- > Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
 - > Bipartisan bill proposed by Representatives Hank Johnson and Martha Roby to purportedly strengthen the abbreviated pathway created for biosimilar drugs
 - > The bill limits the number of patents that drug companies can assert against a biosimilar manufacturer to 20
 - > The limit can be increased if requested in a timely manner and if such a request is made in the interest of justice and for good cause

BIOSIMILAR APPROVALS AND LAUNCHES

US Biosimilar Approvals – 23 total

Drug Name	Approval Date	Drug Name	Approval Date
Hadlima (adalimumab-bwwd)	July 2019	Udenyca (pegfilgrastim-cbqv)	November 2018
Ruxience (rituximab-pvvr)	July 2019	Hyrimoz (adalimumab-adaz)	October 2018
Zirabev (bevacizumab-bvzr)	June 2019	Nivestym (filgrastim-aafi)	July 2018
Kanjinti (trastuzumab-anns)	June 2019	Fulphila (pegfilgrastim-jmdb)	June 2018
Eticovo (entanercept-ykro)	April 2019	Retacrit (epoetin alfa-epbx)	May 2018
Trazimera (trastuzumab-qyyp)	March 2019	Ixifi (infliximab-qbtx)	December 2017
Ontruzant (trastuzumab-dttb)	January 2019	Ogivri (trastuzumab-dkst)	December 2017
Herzuma (trastuzumab-pkrb)	December 2018	Mvasi (bevacizumab-awwb)	September 2017
Truxima (rituximab-abbs)	November 2018	Cyltezo (adalimumab-adbm)	August 2017

US Biosimilar Approvals – 23 total (cont.)

Drug Name	Approval Date
Renflexis (infliximab-abda)	May 2017
Amjevita (adalimumab-atto)	September 2016
Erelzi (etanercept-szzs)	August 2016
Inflectra (infliximab-dyyb)	April 2016
Zarxio (filgrastim-sndz)	March 2015

Contacts



Christopher J. Betti, Ph.D. Chicago T: +1.312.324.1449 christopher.betti@morganlewis.com



Robin M. Silva San Francisco T: +1.415.442.1379 robin.silva@morganlewis.com



Jennifer M. Dienes Chicago T: +1.312.324.1453 jennifer.dienes@morganlewis.com



Our Global Reach

Africa Asia Pacific Europe Latin America Middle East North America

Our Locations

Abu Dhabi Almaty Beijing* Boston Brussels Century City Chicago Dallas Dubai Frankfurt Hartford Hong Kong* Houston London Los Angeles Miami

Moscow New York Nur-Sultan **Orange County** Paris Philadelphia Pittsburgh Princeton San Francisco Shanghai* Silicon Valley Singapore* Tokyo Washington, DC Wilmington



Morgan Lewis

*Our Beijing and Shanghai offices operate as representative offices of Morgan, Lewis & Bockius LLP. In Hong Kong, Morgan Lewis operates through Morgan, Lewis & Bockius, which is a separate Hong Kong general partnership registered with The Law Society of Hong Kong as a registered foreign law firm operating in Association with Luk & Partners. Morgan Lewis Stamford LLC is a Singapore law corporation affiliated with Morgan, Lewis & Bockius LLP.



© 2019 Morgan, Lewis & Bockius LLP © 2019 Morgan Lewis Stamford LLC © 2019 Morgan, Lewis & Bockius UK LLP

Morgan, Lewis & Bockius UK LLP is a limited liability partnership registered in England and Wales under number OC378797 and is a law firm authorised and regulated by the Solicitors Regulation Authority. The SRA authorisation number is 615176.

Our Beijing and Shanghai offices operate as representative offices of Morgan, Lewis & Bockius LLP. In Hong Kong, Morgan Lewis operates through Morgan, Lewis & Bockius, which is a separate Hong Kong general partnership registered with The Law Society of Hong Kong as a registered foreign law firm operating in Association with Luk & Partners. Morgan Lewis Stamford LLC is a Singapore law corporation affiliated with Morgan, Lewis & Bockius LLP.

This material is provided for your convenience and does not constitute legal advice or create an attorney-client relationship. Prior results do not guarantee similar outcomes. Attorney Advertising.

APPENDIX

Legend

Р	Petitioner
РО	Patent Owner
2-Consid.	Secondary Considerations raised by Patent Owner to support nonobviousness
U	Use
F	Formulation
С	Composition
Μ	Method
FWD	Final Written Decision
Pending	IPR has been instituted and is pending an FWD
Institution Denied	PTAB has denied institution of IPR
J/W	Joined with
NA	Not Applicable
Y/N	Yes/No





> 22 IPRs filed challenging 14 different patents

AbbVie Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
8,916,157	Amgen	2015-01514	1/0	Y	F (20-150 mg)	Institution Denied
8,916,158	Amgen	2015-01517	1/0	Y	F (20-150 mg)	Institution Denied
8,889,135	1) Coherus	1) 2016-00172	1) 2/5	1) Y	1) U (RA)	1) FWD – Claims Invalid (Appealed)
	2) Boehringer Ingelheim	2) 2016-00408	2) 2/5	2) Y	2) U	2) FWD – Claims Invalid (Appealed)
	3) Boehringer Ingelheim	3) 2016-00409	3) 2/5	3) Y	3) U	3) FWD – Claims Invalid (Appealed)
9,017,680	Coherus	2016-00188	3/5	Y	U (RA)	FWD – Claims Invalid (Appealed)
9,073,987	Coherus	2016-00189	3/5	Y	U (RA)	FWD – Claims Invalid (Appealed)



> 22 IPRs filed challenging 14 different patents

AbbVie Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
9,114,166	Coherus	2016-01018	2/0	Y	F (50 mg)	Institution Denied
9,085,619	Coherus	 2) 2017-00823 3) 2017-00826 	3) 2/NA 4) 2/NA 5) 2/0	1) Y 2) N 3) Y 4) Y 5) Y 6) Y	F (Bufferless)	 1-2) Institution Denied 3-4) IPRs Dismissed April 11, 2017 * 5-6) Institution Denied
9,067,992	Sandoz	2017-02106	1/1	Y	U (Psoriatic arthritis)	Terminated due to settlement
8,911,737	Sandoz	2017-01987	6/0	Y	U (Crohn's)	Institution Denied
8,974,790	Sandoz	2017-01988	6/0	Y	U (Ulcerative colitis)	Institution Denied
9,090,689	Sandoz	2017-02105	3/2	Y	U (Plaque psoriasis)	Terminated due to settlement
	•					

Morgan Lewis * IPRs 2017-01008 & 2017-01009 replaced IPRs 2017-00826 & 2017-00827

> 22 IPRs filed challenging 14 different patents

AbbVie Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
8,802,100	Sandoz	2017-01823	1/0	Ν	F (45-150 mg)	Institution Denied
9,512,216	Sandoz	 2017-01824 2018-00002 	1) 2/0 2) 2/0	1) Y 2) Y	U (Plaque psoriasis)	 Institution Denied Institution Denied
9,187,559	Sandoz	2018-00156	2/0	Y	U (IBD)	Institution Denied

1. A stable liquid aqueous pharmaceutical formulation comprising

- a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFa) antibody, or an antigen-binding portion thereof, at a concentration of 20 to 150 mg/ml,
- b) a tonicity agent,
- c) a surfactant, and
- d) a buffer system having a pH of 4.0 to 8.0, wherein the antibody comprises the light chain variable region (LCVR) and the heavy chain variable region (HCVR) of D2E7.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Amgen	2015-01514	1-8, 10-13, 15-30	None	1/0	Y	F	Institution Denied

1. A stable liquid aqueous pharmaceutical formulation comprising

- a) a human IgG1 anti-human TNFa antibody, or an antigen-binding portion thereof, at a concentration of 20 to 150 mg/ml,
- b) a tonicity agent,
- c) a surfactant, and
- d) a buffer system having a pH of 4.0 to 8.0, wherein the antibody comprises the LCVR and HCVR of D2E7.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Amgen	2015-01517	1-8, 10-13, 15-30	None	1/0	Y	F	Institution Denied

1. A method for treating rheumatoid arthritis in a human subject by administering subcutaneously a total body dose of 40 mg of a human anti-TNFa antibody once every 13–15 days for a period sufficient to treat the rheumatoid arthritis, wherein the anti-TNFa antibody comprises an IgG1 heavy chain constant region; a variable light (V_L) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (V_H) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (V_H) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (V_H) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (V_H) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (V_H) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:4.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Coherus	2016-00172	1-5	§ 103 for all claims	2/5	Ν	U	FWD – Claims Invalid (Appealed)
Boehringer Ingelheim	2016-00408	1-5	§ 103 for all claims	2/5	Y	U	FWD – Claims Invalid (Appealed)
Boehringer Ingelheim	2016-00409	1-5	§ 103 for all claims	2/5	Y	U	FWD – Claims Invalid (Appealed)

- 1. A method of reducing signs and symptoms in a patient with moderately to severely active rheumatoid arthritis, comprising:
 - a) administering to said patient, in combination with methotrexate, a human anti-TNFa antibody,
 - b) wherein the human anti-TNFa antibody is administered subcutaneously in a total body dose of 40 mg once every 13–15 days, and
 - c) wherein the anti-TNFa antibody comprises an IgG1 heavy chain constant region; a V_L chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a V_H chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6, and a CDR3 having the amino acid sequence of SEQ ID NO:4.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Coherus	2016-00188	1-4	§ 103 for all claims	3/5	Ν	U	FWD – Claims Invalid (Appealed)

- 1. A method of reducing signs and symptoms in a patient with moderately to severely active rheumatoid arthritis, comprising:
 - a) administering to said patient a total body dose of 40 mg of a human anti-TNFa antibody,
 - b) wherein the dose is administered subcutaneously from a 40 mg dosage unit form once every 13–15 days, and
 - c) wherein the anti-TNFa antibody comprises an IgG1 heavy chain constant region; a V_L chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a V_H chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:4.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Coherus	2016-00189	1-2	§ 103 for all claims	3/5	Ν	U	FWD – Claims Invalid (Appealed)

1. A stable liquid aqueous pharmaceutical formulation comprising a human anti-human TNFa IgG1 antibody at a concentration of 50 mg/ml, wherein the antibody comprises the LCVR and HCVR of D2E7, and a buffer system; wherein the formulation is isotonic, suitable for single-use subcutaneous injection, and has a pH of 4.0 to 8.0.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Coherus	2016-01018	1-4, 6-10, 13-16, 23-26, 28	None	2/0	Y	F	Institution Denied

- **16.** An aqueous pharmaceutical formulation comprising:
 - a) an anti-TNFa antibody comprising an LCVR having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:7; and an HCVR having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, wherein the concentration of the antibody is 50 to 200 mg/ml; and
 - b) water; wherein the formulation does not comprise a buffering system.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Coherus	2017-00822	16-19, 24-30	NA	1/0	Y	F	Institution Denied
Coherus	2017-00823	16-19, 24-30	NA	1/0	Ν	F	Institution Denied

- **16.** An aqueous pharmaceutical formulation comprising:
 - a) an anti-TNFa antibody comprising an LCVR having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:7; and an HCVR having a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, wherein the concentration of the antibody is 50 to 200 mg/ml; and
 - b) water; wherein the formulation does not comprise a buffering system.

		Experts		Claim Type	Status
16-19, 24-30	NA	2/NA	Y	F	Dismissed
16-19, 24-30	NA	2/NA	Y	F	Dismissed
16-19, 24-30	NA	2/1	Y	F	Institution Denied
16-19, 24-30	NA	2/1	Y	F	Institution Denied
	16-19, 24-30 16-19, 24-30	16-19, 24-30 NA 16-19, 24-30 NA	16-19, 24-30 NA 2/NA 16-19, 24-30 NA 2/1	16-19, 24-30 NA 2/NA Y 16-19, 24-30 NA 2/1 Y	16-19, 24-30 NA 2/NA Y F 16-19, 24-30 NA 2/1 Y F

 A method of treatment of moderate to severe active psoriatic arthritis in adult patients, wherein each said patient has ≥3 swollen and ≥3 tender joints prior to the treatment and has failed NSAID therapy, comprising subcutaneously administering to each said patient 40 mg of adalimumab every other week, wherein 23% of said patients achieve 70% reduction in American College of Rheumatology (ACR) score at week 24 of the treatment.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Sandoz	2017-02106	1, 2, 5-7	§ 102 for claims 1, 5, 6 § 103 for all claims	1/1	Y	U	Terminated

1. A method for treating Crohn's disease in a human subject by administering subcutaneously a total body dose of 40 mg of a human anti-TNFa antibody once every 13–15 days for a period sufficient to treat Crohn's disease, wherein the anti-TNFa antibody comprises an IgG1 heavy chain constant region; a V_L chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a V_H chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6, and a CDR3 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6, and a CDR3 having the amino acid sequence of SEQ ID NO:4.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Sandoz	2017-01987	1-6	NA	6/0	Y	U	Institution Denied

1. A method for treating ulcerative colitis in a human subject by administering subcutaneously a total body dose of 40 mg of a human anti-TNFa antibody once every 13–15 days for a period sufficient to treat the ulcerative colitis, wherein the anti-TNFa antibody comprises an IgG1 heavy chain constant region; a V_L chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a V_H chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6, and a CDR3 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6, and a CDR3 having the amino acid sequence of SEQ ID NO:4.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Sandoz	2017-01988	1-6	NA	6/0	Y	U	Institution Denied

1. A method of administering adalimumab for treatment of moderate to severe chronic plaque psoriasis by filling adalimumab into vessels and subcutaneously administering 40 mg of said adalimumab every other week.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Sandoz	2017-02105	1, 4, 7, 10, 13, 16, 19	§ 103 for all claims	3/2	Y	U	Terminated

- 1. A stable liquid aqueous pharmaceutical formulation comprising
 - a) a human IgG1 anti-human TNFa antibody, or an antigen-binding portion thereof, at a concentration of 45 to 150 mg/ml,
 - b) a polyol,
 - c) a polysorbate at a concentration of 0.1 to 10 mg/ml, and
 - d) a buffer system having a pH of 4.5 to 7.0, wherein the antibody comprises the LCVR and HCVR of D2E7.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Sandoz	2017-01823	1-29	NA	1/0	Ν	F	Institution Denied

1. A method for treating moderate to severe chronic plaque psoriasis by subcutaneously administering to an adult patient an initial dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week, starting one week after said first dosing, wherein the patient achieves at least Psoriasis Area and Severity Index (PASI) 75 response at week 12 of the treatment.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Sandoz	2017-01824	1-16	NA	2/0	Y	U	Institution Denied
Sandoz	2018-00002	1-16	NA	2/0	Y	U	Institution Denied

- 1. A multiple-variable dose method for treating idiopathic inflammatory bowel disease in a human subject in need thereof, comprising subcutaneously administering to the human subject:
 - a) a first dose of 160 mg of adalimumab administered to the human subject within a day; and
 - a second dose of 80 mg of adalimumab administered to the human subject within a day, wherein the second dose is administered two weeks following administration of the first dose.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Sandoz	2018-00156	1-30	NA	2/0	Y	U	Institution Denied





Rituxan

> 27 IPRs filed challenging 10 different patents

Genentech/ Biogen Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
7,820,161	1) BI	1) 2015-00415	1) 1/0	1) Y	1) U (RA)	1) Petitioner's adverse judgment
	2) Celltrion	2) 2015-01744	2) 1/0	2) Y	2) U	2) Petitioner filed Motion
	 Celltrion Pfizer 	3) 2016-01614 4) 2017-01115	3) 2/1 4) 3/NA	3) Y 4) Y	3) U 4) U	to Dismiss 3) FWD – Claims Valid 4) FWD – Claims Valid (J/W '614)
7,976,838	1) BI	1) 2015-00417	1) 1/0	1) Y	1) U (RA)	1) Petitioner's adverse judgment
	2) Celltrion	2) 2015-01733	2) 1/0	2) Y	2) U	2) Petition filed Motion to
	3) Celltrion	3) 2016-01667	3) 2/0	3) Y	3) U	Dismiss 3) Institution Denied
	4) Pfizer	4) 2017-01923	4) 3/1	4) Y	4) U	4) Terminated – Settled
	5) Sandoz 6) Sandoz 7) Celltrion	5) 2017-02042 6) 2017-02036 7) 2018-01019	5) 2/0 6) 2/0 7) 3/0	5) Y 6) Y 7) Y	5) U 6) U 7) U	 5) Institution Denied 6) Institution Denied 7) Terminated – Settled (J/W 2017-01923)



> 27 IPRs filed challenging 10 different patents

Genentech/ Biogen Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
8,329,172	1) BI	1) 2015-00418	1) 1/0	1) Y	1) U (lymphoma)	1) Institution Denied
	2) Celltrion	2) 2017-01093	2) 2/0	2) Y	2) U	2) Institution Denied
	3) Pfizer	3) 2017-01166	3) 2/0	3) Y	3) U	3) Institution Denied
	4) Pfizer	4) 2018-00285	4) 2/1	4) Y	4) U	4) Terminated – Settled
8,557,244	1) Celltrion	1) 2017-01094	1) 2/0	1) Y	1) U (lymphoma)	1) Institution Denied
	2) Pfizer	2) 2017-01167	2) 2/0	2) Y	2) U	2) Institution Denied
9,296,821	1) Celltrion	1) 2017-01095	1) 2/0	1) Y	1) U (lymphoma)	1) FWD – Claims
	2) Pfizer	2) 2018-00186	2) 2/1	2) Y	2) U	Invalid 2) Terminated

> 27 IPRs filed challenging 10 different patents

Genentech/ Biogen Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
7,682,612	1) Celltrion	1) 2017-01227	1) 1/0	1) Y	1) U (leukemia)	1) Institution Denied
	2) Celltrion	2) 2017-01230	2) 1/0	2) Y	2) U	2) Institution Denied
	3) Pfizer	3) 2017-02126	3) 2/0	3) Y	3) U	3) Institution Denied
8,206,711	1) Celltrion	1) 2017-01229	1) 1/0	1) Y	1) U (leukemia)	1) Institution Denied
	2) Pfizer	2) 2017-02127	2) 2/0	2) Y	2) U	2) Institution Denied
8,821,873	Pfizer	2017-01168	2/1	Y	U (lymphoma)	FWD – Claims Invalid
8,545,843	Pfizer	2018-00086	2/0	Y	U (vasculitis)	Institution Denied
9,504,744	Pfizer	2018-00231	2/0	Y	U (lymphoma)	Terminated

- 1. A method of treating rheumatoid arthritis in a human by administering:
 - a) more than one intravenous dose of a therapeutically effective amount of rituximab; and
 - b) methotrexate.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Boehringer Ingelheim	2015-00415	1-12	§ 103 for claims 1, 2, 5, 6, 9, and 10	1/0	Y	U	Adverse Judgment
Celltrion	2015-01744	1, 2, 5, 6, 9, and 10	None	1/0	Y	U	Dismissed

- 1. A method of treating rheumatoid arthritis in a human by administering:
 - a) more than one intravenous dose of a therapeutically effective amount of rituximab; and
 - b) methotrexate.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Celltrion	2016-01614	1-12	§ 103 for claims 1-3, 5-7, 9-11	2/1	Y		FWD – Claims Valid Celltrion's appeal dismissed as part of litigation settlement (Case No. 18-574-RMB- KMW (D.N.J.))
Pfizer	2017-01115	1-12	§ 103	3/NA	Y	U	FWD – Claims Valid (J/W '614)

1. A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNFa-inhibitor by administering an antibody that binds to CD20, wherein the antibody is administered as two intravenous doses of 1,000 mg.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Boehringer Ingelheim	2015-00417	1-14	§ 103 for all claims	1/0	Y	U	Adverse Judgment
Celltrion	2015-01733	1-14	NA	1/0	Y	U	Dismissed
Celltrion	2016-01667	1-14	NA	2/0	Y	U	Institution Denied
Pfizer	2017-01923	1-14	§ 103 for all claims	3/1	Y	U	Terminated – Settled

1. A method of treating rheumatoid arthritis in a human patient who experiences an inadequate response to a TNFa-inhibitor by administering an antibody that binds to CD20, wherein the antibody is administered as two intravenous doses of 1,000 mg.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Sandoz	2017-02036	1-14	NA	2/0	Y	U	Institution Denied
Sandoz	2017-02042	1-14	NA	2/0	Y	U	Institution Denied
Celltrion	2018-01019	1-14	§ 103 for all claims	3/0	Y	U	Terminated – Settled (J/W 2017- 01923)

1. A method of treating low-grade B-cell non-Hodgkin's lymphoma (NHL) in a human patient by administering chemotherapy consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy) to which the patient responds, followed by rituximab maintenance therapy, wherein the maintenance therapy comprises four weekly administrations of rituximab at a dose of 375 mg/m² every six months, and wherein the maintenance therapy is provided for two years.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Boehringer Ingelheim	2015-00418	1	NA	1/0	Ν	U	Institution Denied
Celltrion	2017-01093	1	NA	2/0	Y	U	Institution Denied
Pfizer	2017-01166	1	NA	2/0	Y	U	Institution Denied
Pfizer	2018-00285	1	§ 103	2/1	Y	U	Terminated - Settled

1. A method of treating a patient with diffuse large-cell lymphoma by administering an unlabeled chimeric anti-CD20 antibody and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) chemotherapy to the patient, wherein the patient is >60 years old and has bulky disease (tumor >10 cm in diameter).

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Celltrion	2017-01094	1-2	NA	2/0	Y	U	Institution Denied (Request for Rehearing Denied)
Pfizer	2017-01167	1-2	NA	2/0	Y	U	Institution Denied

1. A method for treating low-grade or follicular NHL by administering to a patient a therapeutically effective amount of rituximab during a chemotherapeutic regimen, wherein the chemotherapeutic regimen consists of CVP therapy, wherein the method comprises administering 375 mg/m² of rituximab, and wherein the method provides a beneficial synergistic effect in the patient.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Celltrion	2017-01095	1-6	§ 102 for all claims§ 103 for all claims	2/0	Y	U	FWD – Claims Invalid
Pfizer	2018-00186	1-6	§ 102 for claims 4-6 § 103 for all claims	2/1	Y	U	Terminated



1. A method of treating chronic lymphocytic leukemia (CLL) in a human patient by administering an anti-CD20 antibody in an amount effective to treat the CLL, wherein the method does not include treatment with a radiolabeled anti-CD20 antibody.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Celltrion	2017-01227	23-57	NA	1/0	Y	U	Institution Denied
Celltrion	2017-01230	1-22, 58-60	NA	1/0	Y	U	Institution Denied
Pfizer	2017-02126	1-13, 15-35, 37-60	NA	2/0	Y	U	Institution Denied

1. A method of treating CLL in a human patient by administering rituximab in an amount effective to treat the CLL, wherein the rituximab is administered to the patient at a dosage of 500 mg/m².

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Celltrion	2017-01229	1-9	NA	1/0	Y	U	Institution Denied
Pfizer	2017-02127	1-9	NA	2/0	Y	U	Institution Denied

1. A method of treating a patient with diffuse large-cell lymphoma by administering anti-CD20 antibody and chemotherapy, wherein the patient is >60 years old, wherein the chemotherapy comprises CHOP, and wherein the anti-CD20 antibody is administered in combination with a stem cell transplantation regimen.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Pfizer	2017-01168	1-5	§ 103	2/1	Y	U (lymphoma)	FWD – Claims Invalid

1. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising administering to the human a therapeutically effective amount of rituximab, wherein the administration of the rituximab consists of intravenous administration.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Pfizer	2018-00086	1-12	NA	2/0	Y	U (vasculitis)	Institution Denied

1. A method of treating a >60-year-old diffuse large-cell lymphoma patient comprising administering anti-CD20 antibody and CHOP chemotherapy to the patient, wherein the anti-CD20 antibody is administered to the patient in combination with a transplantation regimen.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Pfizer	2018-00231	1-16	NA	2/0	Y	U (vasculitis)	Terminated

HERCEPTIN

Herceptin

> 36 IPRs filed challenging 12 different patents

Genentech Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
8,337,856 (Kadcyla)	Phigenix	2014-00676	1/4	Y	С	FWD – Claims Valid
7,575,748	Phigenix	2014-00842	1/0	Y	U	Institution Denied
6,407,213	 Mylan Mylan Celltrion Celltrion 5) Pfizer	 1) 2016-01693 2) 2016-01694 3) 2017-01373 4) 2017-01374 5) 2017-01488 	1) 2/0 2) 2/0 3) 2/4 4) 2/4 5) 2/1	1) Y 2) Y 3) Y 4) Y 5) Y	1) C 2) C 3) C 4) C 5) C	 Terminated (Settled) Terminated (Settled) FWD – Claims Invalid (some) Adverse Judgment
	6) Pfizer7) BI	 6) 2017-01489 7) 2017-02032 	 6) 2/1 7) 1/0 	6) Y 7) Y	6) C 7) C	 8) Adverse Judgment 9) FWD – Claims Invalid (some) (J/W '488) 10) FWD – Claims Invalid (some) (J/W
	8) BI 9) Samsung Bioepis 10) Samsung Bioepis	8) 2017-02031 9) 2017-02139 10) 2017-02140	8) 1/0 9) 4/NA 10) 4/NA	8) Y 9) Y 10) Y	8) C 9) C 10) C	[′] 489)

> 36 IPRs filed challenging 12 different patents

Genentech Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
7,807,799	Hospira	2016-01837	1/2	Y	Μ	FWD – Claims Invalid (Appealed)
7,846,441	1) Hospira	1) 2017-00731	1) 4/2	1) Y	1) U	1) FWD – Claims Invalid (Appealed)
	2) Celltrion	2) 2017-01121	2) 3/2	2) Y	2) U	 2) FWD – Claims Invalid (Appealed) 3) FWD – Claims Invalid (J/W '121)
	3) Pfizer	3) 2017-02063	3) 1/NA	3) Y	3) U	4) Institution Denied5) Institution Denied
	4) Pfizer 5) Samsung	4) 2018-00016 5) 2018-00192	4) 1/1 5) 2/0	4) Y 5) Y	4) U 5) U	
	Bioepis					
6,627,196	1) Hospira	1) 2017-00804	1) 2	1) Y	1) U	1) FWD – Claims Valid (Appealed)
	2) Samsung Bioepis	2) 2017-01958	2) 3/NA	2) Y	2) U2) FWD - Claims Valid (J/W '8 3) FWD - Claims Valid (Appeale	3) FWD – Claims Valid (J/W 804)
	3) Celltrion	3) 2017-01139	3) 1/2	3) Y	3) U	

> 36 IPRs filed challenging 12 different patents

Genentech Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
7,371,379	1) Hospira	1) 2017-00805	1) 2	1) Y	1) U	1) FWD – Claims Valid (Appealed)
	2) Samsung Bioepis	2) 2017-01959	2) 2/NA	2) Y	2) U	2) FWD – Claims Valid (J/W '805)
	3) Celltrion	3) 2017-01140	3) 1/0	3) Y	3) U	3) FWD – Claims Valid (Appealed)
8,591,897	1) Pfizer 2) Pfizer	1) 2017-01726 2) 2017-01727	1) 3/NA 2) 3/NA	1) Y 2) Y	1) U 2) U	 1) Institution Denied 2) Institution Denied
	3) Celltrion	3) 2017-00959	3) 1/NA	3) Y	3) U	3) Terminated
6,339,142	1) Pfizer 2) Pfizer	1) 2017-02019 2) 2018-00330	1) 2/3 2) 3/0	1) Y 2) Y	1) C 2) C	 1) Terminated 2) Institution Denied
9,249,218	1) Pfizer 2) Pfizer	1) 2017-02020 2) 2018-00331	1) 2/3 2) 1/0	1) Y 2) Y	1) F 2) F	 1) Terminated 2) Institution Denied

> 36 IPRs filed challenging 12 different patents


Genentech Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
7,892,549	 Hospira Hospira Hospira Celltrion Samsung Bioepis 	 1) 2017-00737 2) 2017-00739 3) 2017-01122 4) 2017-01960 	1) 1/2 2) 1/0 3) 1/2 4) 2/NA	1) Y 2) N 3) Y 4) Y	1) U 2) U 3) U 4) U	 FWD – Claims Invalid (Appealed) Institution Denied FWD – Claims Invalid (Appealed) FWD – Claims Invalid (J/W '737)
8,314,225* *Also being asserted regarding Rituxan	Pfizer	2018-01219	1/0	Y	C	Instituted - Roche disclaimed all claims except daim 20 and argued that institution should be denied because the patent is under ex parte reexamination - Petitioner Reply filed



1. An immunoconjugate comprising an anti-ErbB2 antibody conjugated to a maytansinoid, wherein the antibody is huMAb4D5-8.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Phigenix	2014-00676	1-8	§ 103 for all claims	1/4	Ν	С	FWD – Claims Valid

1. A method for the treatment of a tumor in a mammal, comprising the steps of (i) identifying said tumor as being characterized by overexpression of an ErbB2 receptor and as being a tumor that does not respond, or responds poorly, to treatment with an anti-ErbB antibody, and (ii) intravenously administering to the mammal a therapeutically effective amount of a conjugate of a humanized antibody huMab 4D5-8 covalently linked via a thioether linking group with a maytansinoid DM1 having the structure at a dose of between about 0.2 mg/kg and about 10 mg/kg (antibody-maytansinoid conjugate weight/body weight) and at a frequency of dosing selected from the group of dosing frequencies consisting of bolus, less than about one time per week, one time per week, two times per week, more than two times per week, and continuous infusion, whereby said tumor characterized by overexpression of an ErbB2 receptor and that does not respond, or responds poorly, to treatment with an anti-ErbB antibody, is treated.



Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Phigenix	2014-00842	1-20, 25-27	NA	1/0	Ν	U	Institution Denied

1. A humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues that bind an antigen incorporated into a human antibody variable domain, and further comprising a Framework Region (FR) amino acid substitution at a site selected from the group consisting of 4L, 38L, 43L, 44L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, and 92H, utilizing the numbering system set forth in Kabat.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Mylan	2016-01693	1, 2, 4, 12, 25, 29- 31, 33, 42, 60, 62- 67, 69, 71-81	NA	2/4	Y	С	Settled
Mylan	2016-01694	1, 2, 4, 12, 25, 29- 31, 33, 42, 60, 62- 67, 69, 71-81	NA	2/4	Y	С	Settled
Celltrion	2017-01374	1-2, 4, 12, 25, 29- 31, 33, 42, 60, 62- 67, 69, 71-81	 § 102 for daims 1, 2, 4, 25, 29, 62-64, 66, 67, 71, 72, 75, 76, 80, 81 § 103 for daims 1, 2, 4, 12, 25, 29, 30, 31, 33, 42, 60, 62-67, 69, 71-81 		Y	С	FWD – Claims Invalid (1, 2, 4, 25, 29, 30, 31, 33, 62-64, 66, 67, 69, 72, 78, 80, 81)
Celltrion	2017-01373	1-2, 4, 12, 25, 29- 31, 33, 42, 60, 62- 67, 69, 71-81	§ 103 for all daims	2/4	Y	С	FWD – Claims Invalid (1, 2, 4, 12, 25, 29, 30, 31, 33, 42, 60, 62-64, 66, 67, 69, 71, 73, 74, 78, 80, 81)



1. A humanized antibody variable domain comprising non-human CDR amino acid residues that bind an antigen incorporated into a human antibody variable domain, and further comprising an FR amino acid substitution at a site selected from the group consisting of 4L, 38L, 43L, 44L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, and 92H, utilizing the numbering system set forth in Kabat.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Pfizer	2017-01488	1-2, 4, 12, 25, 29-31, 33, 42, 60, 62-67, 69, 71-81	§ 102 for daims 1, 2, 4, 25, 29, 62-64, 66, 67, 71, 72, 75, 76, 80, 81 § 103 for daims 1, 2, 4, 12, 25, 29, 30, 31, 33, 42, 60, 62-67, 69, 71-81	2/1	Y	С	FWD – Claims Invalid (1, 2, 4, 25, 29, 30, 31, 33, 62-64, 66, 67, 69, 72, 78, 80, 81)
Pfizer	2017-01489	1-2, 4, 12, 25, 29, 62- 67, 69, 71-81	§ 103 for all daims	2/1	Y	С	FWD – Claims Invalid (1, 2, 4, 12, 25, 29, 30, 31, 33, 42, 60, 62-64, 66, 67, 69, 71, 73, 74, 78, 80, 81)
BI	2017-02032	1-2, 4, 25, 29, 62-64, 66-67, 71-73, 75-78, 80-81	§ 102 for daims 1-2, 4, 25, 62-64, 66, 67, 69, 71, 73, 75, 78, 80, 81 § 103 for daims 1, 2, 4, 25, 29, 62-64, 66, 67, 69, 71-73, 75-78, 80-81	1/0	Y	С	Adverse Judgment



1. A humanized antibody variable domain comprising non-human CDR amino acid residues that bind an antigen incorporated into a human antibody variable domain, and further comprising an FR amino acid substitution at a site selected from the group consisting of 4L, 38L, 43L, 44L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, and 92H, utilizing the numbering system set forth in Kabat.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
BI	2017-02031	1-2, 4, 25, 29, 62-64, 66-67, 69, 71, 75-76, 78, 8-81	§ 102 for daim 63 § 103 for daims 1, 2, 4, 25, 29, 62, 64, 66, 69, 71, 73, 75-78, 80, 81	1/0	Y	С	Adverse Judgment
Samsung Bioepsis	2017-02140	1-2, 4, 12, 25, 29, 62- 67, 69, 71-81	NA	4/NA	Y	С	FWD – Claims Invalid (1, 2, 4, 12, 25, 29, 30, 31, 33, 42, 60, 62-64, 66, 67, 69, 71, 73, 74, 78, 80, 81) (J/W '489)
Samsung Bioepsis	2017-02139		 § 102 for daims 1, 2, 4, 25, 29, 62-64, 66, 67, 71, 72, 75, 76, 80, 81 § 103 for daims 1, 2, 4, 12, 25, 29, 30, 31, 33, 42, 60, 62-67, 69, 71- 81 	4/NA	Y	С	FWD – Claims Invalid (1, 2, 4, 25, 29, 30, 31, 33, 62-64, 66, 67, 69, 72, 78, 80, 81) (J/W '488)

1. A method of purifying a protein that comprises a CH2/CH3 region by subjecting a composition of said protein to protein A affinity chromatography at a temperature in the range from about 10°C to about 18°C.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Hospira	2016-01837	1-3, 5-11	§ 102 for claims 1, 2, and 5 § 103 for claims 1-3, 5-11	1/2	Y	Μ	FWD – Claims Invalid Genentech appealed; includes a constitutional challenge



Morgan Lewis

Representative Claim

1. A method for the treatment of a human patient with breast cancer that overexpresses ErbB2 receptor, comprising administering a combination of an antibody that binds ErbB2, a taxoid, and a further growth inhibitory agent to the human patient in an amount effective to extend the time to disease progression in the human patient, wherein the antibody binds to epitope 4D5 within the ErbB2 extracellular domain sequence.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Hospira	2017-00737	1-17	§ 103	1/2	Y	U	FWD – Claims Invalid (Appealed) Denied PO's Motion to Amend
Hospira	2017-00739	1-11, 14-17	NA	1/0	Ν	U	Institution Denied



1. A method for the treatment of a human patient with breast cancer that overexpresses ErbB2 receptor, comprising administering a combination of an antibody that binds ErbB2, a taxoid, and a further growth inhibitory agent to the human patient in an amount effective to extend the time to disease progression in the human patient, wherein the antibody binds to epitope 4D5 within the ErbB2 extracellular domain sequence.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Celltrion	2017-01122	1-11, 14-17	§ 103	1/2	Y	U	FWD – Claims Invalid (Appealed)
Samsung Bioepis	2017-01960	1-17	§ 103	2/NA	Y	U	FWD – Claims Invalid (J/W 737)

Herceptin

Representative Claim

1. A method for the treatment of a human patient with a malignant progressing tumor or cancer characterized by overexpression of ErbB2 receptor by administering a combination of an intact antibody that binds to epitope 4D5 within the ErbB2 extracellular domain sequence and a taxoid, in the absence of anthracycline derivative, to the human patient in an amount effective to extend the time to disease progression in said human patient, without increase in overall severe adverse events.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Hospira	2017-00731	1-14	§ 103	4/2	Y	U	FWD – Claims Invalid (Appealed)
Celltrion	2017-01121	1-14	§ 103	3/2	Y	U	FWD – Claims Invalid (Appealed)
Pfizer	1) 2017-02063	1) 1-14	1) § 103 2) NA	1/3	1) Y	1) U	1) FWD – Claims Invalid (J/W '121)
	2) 2018-00016	2) 1-14		1/1	2) Y	2) U	2) Institution Denied
Samsung Bioepsis	2018-00192	1-14	NA	2/0	Y	U	Institution Denied



- 1. A method for the treatment of a human patient diagnosed with cancer characterized by overexpression of ErbB2 receptor by administering an effective amount of an anti-ErbB2 antibody to the human patient, giving:
 - a) an initial dose of at least approximately 5 mg/kg of the anti-ErbB2 antibody; and
 - b) a plurality of subsequent doses of the antibody in an amount that is approximately the same or less than the initial dose, wherein the subsequent doses are separated in time from each other by at least two weeks.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Hospira	2017-00804	1-3, 5, 7, 9- 11, 17-33	§ 103	2	Y	U	FWD – Claims Valid (Appealed)
Samsung Bioepis	2017-01958	1-3, 5, 7, 9- 11, 17-33	§ 103	3/NA	Y	U	FWD – Claims Valid (J/W <i>'</i> 804)
Celltrion	2017-01139	1-3, 5, 7, 9- 11, 17-33	§ 103	1/2	Y	U	FWD – Claims Valid (Appealed)



Morgan Lewis

Representative Claim

- 1. A method for the treatment of a human patient diagnosed with cancer characterized by overexpression of ErbB2 receptor by administering an effective amount of an anti-ErbB2 antibody to the human patient, giving:
 - a) an initial dose of at least approximately 5 mg/kg of the anti-ErbB2 antibody;
 - a plurality of subsequent doses of the antibody in an amount that is approximately the same or less than the initial dose, wherein the subsequent doses are separated in time from each other by at least two weeks; and
 - c) an effective amount of a chemotherapeutic agent.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Hospira	2017-00805	1-3, 5, 7, 9-11, 16-28, 30-40	§ 103	2/NA	Y	U	FWD – Claims Valid (Appealed)
Celltrion	2017-01140	1-3, 5, 7, 9-11, 13-28, 30-40	§ 103	1/0	Y	U	FWD – Claims Valid (Appealed)

- 1. A method for the treatment of a human patient diagnosed with cancer characterized by overexpression of ErbB2 receptor by administering an effective amount of an anti-ErbB2 antibody to the human patient, giving:
 - a) an initial dose of at least approximately 5 mg/kg of the anti-ErbB2 antibody;
 - a plurality of subsequent doses of the antibody in an amount that is approximately the same or less than the initial dose, wherein the subsequent doses are separated in time from each other by at least two weeks; and
 - c) an effective amount of a chemotherapeutic agent.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Samsung Bioepis	2017-01959	1-3, 5, 7, 9-11, 16-28, 30-40	NA	2/NA	Y	U	FWD – Claims Valid (J/W ['] 805)



1. A method of adjuvant therapy by administering to a human subject with nonmetastatic HER2 positive breast cancer, following definitive surgery, anthracycline/cyclophosphamide (AC) based chemotherapy, followed by sequential administration of a taxoid and trastuzumab, or an antibody that blocks binding of trastuzumab to HER2.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Pfizer	2017-01726	1-13	NA	3/NA	Y	U	Institution Denied
Pfizer	2017-01727	1-13	NA	3/NA	Y	U	Institution Denied
Celltrion	2017-00959	1-13	NA	1/NA	Y	U	Terminated – Adverse Judgment



1. A composition of a mixture of anti-HER2 antibody and one or more acidic variants thereof, wherein the amount of the acidic variant(s) is less than about 25%.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Pfizer	2017-02019	1-3	NA	2/3	Y	С	Terminated
Pfizer	2018-00330	1-3	NA	3/0	Y	С	Institution Denied

- 1. A therapeutic composition of a mixture of anti-HER2 antibody and one or more acidic variants thereof, wherein:
 - a) the amount of the acidic variant(s) is less than about 25%,
 - b) the acidic variant(s) are predominantly deamidated variants, wherein one or more asparagine residues of the anti-HER2 antibody have been deamidated,
 - c) the anti-HER2 antibody is humMAb4D5-8,
 - d) the deamidated variants have Asn30 in CDR1 of either or both VL regions of humMAb4D5-8 converted to aspartate, and
 - e) a pharmaceutically acceptable carrier.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Pfizer	2017-02020	1, 5-7	NA	2/3	Y	С	Terminated
Pfizer	2018-00331	1-20	NA	1/0	Y	С	Institution Denied



1. A nucleic acid encoding the amino acid sequence of the C-terminal part of the CH3-domain of an immunoglobulin of the class IgA or IgG, or the amino acid sequence of the C-terminal part of the CH4-domain of an immunoglobulin of the class IgE or IgM, wherein the glycine-lysine-dipeptide comprised in said amino acid sequence of the C-terminal part of the CH3- or CH4-domain is encoded by one of the following nucleic acid sequences: ggaaca, ggcaac, gggaaa, ggaaag, ggcaag, and gggaag; the nucleic acid ggaaaa; or the nucleic acid ggcaaa.

*Also being asserted regarding Rituxan

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Pfizer	2018-01219	1-5, 10-12, 20	§§ 102, 103 for claim 20	1/0	Υ	С	Instituted - Roche disclaimed all claims except claim 20 and argued that institution should be denied because the patent is under <i>ex parte</i> reexamination - Petitioner Reply filed







> Three IPRs filed challenging three different patents

Biogen Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
8,815,236	Swiss Pharma	2016-00912	5/0	Ν	U	Institution Denied
8,349,321	Swiss Pharma	2016-00915	4/0	Ν	F	Institution Denied
8,900,577	Swiss Pharma	2016-00916	4/0	Ν	F	Institution Denied

Tysabri

1. A method of treatment by administering to a patient with multiple sclerosis a therapeutic amount of a stable, aqueous pharmaceutical formulation of about 20 mg/ml to about 150 mg/ml of natalizumab, about 10 mM phosphate buffer, about 140 mM sodium chloride, and polysorbate 80 present in an amount of about 0.001% to 2% (w/v).

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Swiss Pharma	2016-00912	1-16, 21-22	None	5/0	Y	U	Institution Denied



Tysabri

1. A stable, aqueous pharmaceutical formulation of 20 mg/ml of natalizumab, about 10 mM sodium phosphate buffer, 8.18 mg/ml of sodium chloride, and 0.2 mg/ml of polysorbate 80, and wherein the formulation has a pH of 6.1.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Swiss Pharma	2016-00915	1-4	None	4/0	Y	F	Institution Denied

Tysabri

1. A stable, aqueous pharmaceutical formulation of about 20 mg/ml to about 150 mg/ml of natalizumab, polysorbate 80 present in an amount of about 0.001% to 2% (w/v), about 10 mM phosphate buffer, and about 140 mM NaCl.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Swiss Pharma	2016-00916	1, 3-7, 9-12	None	4/0	Y	F	Institution Denied







> Four IPRs filed challenging two patents

Ono Pharm. Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
9,067,999	 Merck Merck 	 2016-01217 2016-01218 	1) 1/NA 2) 1/NA	1) NA 2) NA	1) U 2) U	 Settled Settled
9,073,994	1) Merck	1) 2016-01219	1) 1/NA	1) NA	1) U	1) Settled
	2) Merck	2) 2016-01221	2) 1/NA	2) NA	2) U	2) Settled



1. A method of treating a lung cancer comprising administering a composition comprising a human or humanized anti-PD-1 monoclonal antibody to a human with the lung cancer, wherein the administration of the composition treats the lung cancer in the human.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Merck	2016-01217	1, 6-14, 19-20, 24- 27, and 29-30	§§ 102, 103 for all claims	1/NA	NA	U	Settled
Merck	2016-01218	1, 6-14, 19-20, and 24-27, and 29-30	§§ 102, 103 for all claims	1/NA	NA	U	Settled

1. A method of treating a metastatic melanoma comprising intravenously administering an effective amount of a composition comprising a human or humanized anti–PD-1 monoclonal antibody and a solubilizer in a solution to a human with the metastatic melanoma, wherein the administration of the composition treats the metastatic melanoma in the human.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Merck	2016-01219	1-3, 8-9, 14-15, 19-22 and 25-26	§§ 102, 103 for all daims	1/NA	NA	U	Settled
Merck	2016-01221	1-3, 8-9, 14-15, 19-22, and 25-26	§§ 102, 103 for all claims	1/NA	NA	U	Settled







> Two IPRs filed challenging two patents

Genentech Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
7,622,115	Hospira	2016-01771	1/2	Y	U	FWD – Claims Invalid; Genentech appealed
9,795,672	Pfizer	2018-00373	1/0	Y	U	Institution Denied





1. A method for treating cancer in a patient by administering an effective amount of bevacizumab and assessing the patient for gastrointestinal perforation.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Hospira	2016-01771	1-5	§§ 102, 103 for all daims	1/2	Y	U	FWD – Claims Invalid Genentech appealed, includes a constitutional challenge



1. A method for treating cancer in a patient by administering an effective amount of bevacizumab and assessing the patient for gastrointestinal perforation.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Pfizer	2018-00373	1-18	NA	1/0	Y	U	Institution Denied











> One IPR filed challenging one patent

Representative Claim

1. A method of administering at least one EPO dose to a patient according to an EPO dosing regimen, wherein said regimen maintains at least a serum EPO concentration above a predose level for about five to about 30 days between doses.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Hospira	2013-00365	1-7, 12, 14-28	NA	3/0	NA	U	Not instituted; Janssen disclaimed all of the challenged claims









> One IPR filed challenging one patent

Representative Claim

1. A stable formulation suitable for subcutaneous administration of at least 100mg/ml CTLA4Ig molecule, a sugar selected from the group consisting of sucrose, lactose, maltose, mannitol and trehalose and mixtures thereof, and a pharmaceutically acceptable aqueous carrier, wherein the formulation has a pH range of from 6 to 8, viscosity from 9 to 20 cps, and the weight ratio of sugar:protein of 1.1:1 or higher.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Momenta	2015-01537	1-15	§ 103	1/2	Y	F	FWD – Claims Valid Momenta Appealed (Case No. 17-1694) Momenta ordered to show cause as to why appeal should not be dismissed as moot due to lack of Article III standing









Neulasta-Related IPRs

> Four IPRs filed challenging four patents

Amgen Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
8,952,138	Apotex	2016- 01542	1/1	Ν	Μ	FWD – Claims 1-17 and 19-24 unpatentable Claim 18 patentable (non-aerobic) Request for Rehearing denied Appealed
9,856,287	Fresenius Kabi	2019- 00971	1/0	Y	М	Pending
8,940,878	Kashiv Biosciences	2019- 00791	1/0	Y	М	Pending
9,643,997	1) Kashiv Biosciences	1) 2019- 00797	1) 1/0	1) Y	1) M	1) Pending
	1) Fresenius Kabi	1) 2019- 01183	2) N/A	2) Y	2) M	2) Pending
Morgan Lewi	is					

8,952,138 IPR

Representative Claim

- 1. A method of refolding a protein expressed in a non-mammalian expression system and present in a volume at a concentration of 2.0 g/L or greater that includes:
 - a) contacting the protein with a refold buffer that has a redox component with a final thiol-pair ratio in the range of 0.001 to 100, a redox buffer strength of 2 mM or greater, and one or more of:
 - a denaturant;
 - ii. an aggregation suppressor; and
 - iii. a protein stabilizer;
 - iv. to form a refold mixture;
 - b) incubating the refold mixture; and
 - c) isolating the protein from the refold mixture.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Apotex	2016-01542	1-24	§ 103 for all claims	1/1	Ν	Μ	FWD – Claims 1-17 and 19-24 unpatentable Claim 18 patentable (non-aerobic) Request for Rehearing denied Appealed



9,856,287 IPR

Representative Claim

- 1. A method of refolding proteins expressed in a non-mammalian expression system, the method comprising:
 - a) contacting the proteins with a preparation that supports the renaturation of at least one of the proteins to a biologically active form, to form a refold mixture, the preparation comprising:
 - i. at least one ingredient selected from the group consisting of a denaturant, an aggregation suppressor and a protein stabilizer;
 - ii. an amount of oxidant; and
 - iii. an amount of reductant,
 - iv. wherein the amounts of the oxidant and the reductant are related through a thiol-pair ratio and a thiol-pair buffer strength,
 - v. wherein the thiol-pair ratio is in the range of 0.001-100; and
 - vi. wherein the thiol-pair buffer strength maintains the solubility of the preparation; and
 - vii. incubating the refold mixture so that at least about 25% of the proteins are properly refolded.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Fresenius Kabi	2019-00971	1, 4-6, 8-10, 12, 14-16, 19- 21, 23-26, 29- 30	N/A	N/A	Y	Μ	Pending



8,940,878 IPR

Representative Claim

- 1. A method of purifying a protein expressed in a non-native soluble form in a non-mammalian expression system comprising:
 - a) lysing a non-mammalian cell in which the protein is expressed in a non-native soluble form to generate a cell lysate;
 - b) contacting the cell lysate with a separation matrix under conditions suitable for the protein to associate with the separation matrix;
 - c) washing the separation matrix; and
 - d) eluting the protein from the separation matrix, wherein the separation matrix is an affinity resin selected from the group consisting of Protein A, Protein G and a synthetic mimetic affinity resin.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Kashiv Biosciences	2019-00791	7-8, 11-13, 15- 19, 21	N/A	N/A	Y	Μ	Pending

9,643,997 IPR

Representative Claim

- 1. A method of purifying a protein expressed in a non-native soluble form in a non-mammalian expression system comprising:
 - a) lysing a non-mammalian cell in which the protein is expressed in a non-native soluble form to generate a cell lysate;
 - b) contacting the cell lysate with a separation matrix under conditions suitable for the protein to associate with the separation matrix;
 - c) washing the separation matrix; and
 - d) eluting the protein from the separation matrix.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Kashiv Biosciences	2019-00797	9-10, 13-15, 17-21, 23, 26- 30	N/A	N/A	Y	Μ	Pending









> Three IPRs filed challenging two patents

Hofmann- LaRoche Patent	Challenger(s)	IPR No.	# P / PO Experts	2-Consid.	Claim Type	Status
8,163,522	Coalition for 2015-01792 Affordable Drugs (Kyle Bass)	2015-01792	1/0	Y	М	Institution Denied
	Coherus	2017-01916	1/2	Y	М	Institution Denied
8,063,182	Coherus	2017-02066	1/2	Y	С	Institution Denied

- 1. A method comprising the steps of:
 - a) culturing a host cell with a polynucleotide, wherein the polynucleotide encodes a protein consisting of:
 - i. the extracellular region of an insoluble human TNF receptor, wherein the insoluble human TNF receptor has an apparent molecular weight of about 75 kilodaltons as determined on a non-reducing SDS-polyacrylamide gel and the amino acid sequence LPAQVAFXPYAPEPGSTC (SEQ ID NO:10), and
 - ii. all of the domains of the constant region of a human IgG immunoglobulin heavy chain other than the first domain of said constant region, and
 - b) purifying an expression product of the polynucleotide from the cell mass or the culture medium.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Coalition for Affordable Drugs (Kyle Bass)	2015-01792	1-10	NA	1/0	Y	М	Institution Denied
Coherus	2017-01916	1-10	NA	1/2	Y	М	Institution Denied



1. An isolated antibody that binds specifically to the polypeptide of SEQ ID NO:548.

Challenger(s)	IPR No.	Challenged Claims	Instituted Grounds	# P / PO Experts	2-Consid.	Claim Type	Status
Coherus	2017-02066	2-36	NA	1/2	Y	С	Institution Denied

